Embracing big data and emerging technologies in drug safety

Which new approaches are pharma companies taking to exploit opportunities offered by big data? We’ll be answering this question and many more as we discuss big data and related innovative technologies at World Drug Safety Congress Europe. Hear from a plethora of thought leaders who will be sharing real life examples of how to develop big data programmes and social media …

Top 50 Pharmaceutical Companies 2014

Who are the top pharmaceutical companies in the world and what are they worth in 2014? The Pharmaceutical and Biotechnology continue to dominate the world’s R&D expenditure, with more companies in the top 10 than any other sector. This year, whilst Novartis has knocked Roche from their top spot, individual R&D spends by pharma and biotechs fail to compete with …

Clinical Trial Management System Market, Trends and Forecasts

A new report has stated that the global Clinical Trial Management System (CTMS) market “is expected to grow at a CAGR (compound annual growth rate) of 14% from 2014 to 2019, to reach an estimated value of USD 1,848.5 million in 2019”, compared with USD 844.0 million in 2013. CTMS is a software system which manages clinical trials in clinical …

big data big pharma

Announcing The Marriage of Big Pharma and Big Data

Novartis teams up with Google to develop “smart” lens This week a partnership between Goggle and Novartis has been announced, for the development of a “smart” contact lens to help diabetics track their blood sugar levels. This is the first big partnership made public between big pharma and big data to work together to revolutionise chronic disease monitoring and treatment. …

clinical trials briefing - another u turn for clinical trials regulation

It’s another U-Turn for Clinical Trials Regulation!

In May the EMA announced plans that clinical trial study reports could only be accessed via a ‘view on screen only’ mode, as per the new Clinical Trials Regulation. This was a seeming u-turn on their previous plans for transparency  and aiding researchers in accessing information, thus giving rise to the European Ombudsmen and the IQWiG to attack the plans. …

Download: Exploring the global Pharma M&A market

Andrew Badrot, Founder of CMS Pharma kindly shared his thoughts on the Pharma M&A market, the challenges being faced and what companies can do to overcome the hurdles. Download a copy here The Pharma Mergers and Acquisitions market has recently seen a lot of traffic, with deals between GlaxoSmithKline and Novartis, whilst Pfizer has made overtures to AstraZeneca. With activity …

Pharma M&A AstraZeneca and Pfizer bid of interest

Pharma M&A Games Afoot: Pfizer is interested in AstraZeneca

AstraZeneca’s shares increased 15% on Monday morning, after US drugs giant Pfizer announced its interest in acquiring the UK company. This is the second time the company has approached AstraZeneca within a short time frame. City analyst, Andrew Baum, believed that there was now a 90% chance that Pfizer would achieve its objectives.   Pfizer approached AstraZeneca in January, with …

Pharma M&A Stocks Soaring due to Glaxo and Novartis deal

Pharma M&A activity spurring stocks higher and higher

UK Stocks in Novartis, AstraZeneca and GlaxoSmithKline rose for a third day yesterday, amid Glaxo’s transaction with Novartis and rumors of a takeover of AstraZeneca by Pfizer. It seems that investors are focusing on the pharmaceuticals M&A industry to shore up global stock markets.   As reported in The Guardian the drugs industry was gripped by ‘merger and acquisition fever’ …

Download: The role of big pharma interview with Rino Rappuoli

What is the role of big pharma? This is what we asked Dr Rino Rappuoli, Global Head of Vaccines Research, Novartis Vaccines and Diagnostics in our series Vaccine Viewpoints. “How do you feel the role of big pharma is going to change in the vaccine industry in the coming year, and what are Novartis doing to ensure continuing success? Overall, I think companies …